Pharma News News 11 November 2025 - 30 November 2025

January 19, 2026, 11:10 AM EST. Pfizer (PFE) is scheduled to report Q4 and full-year 2025 earnings on Feb. 3. While oncology sales account for over 28% of revenues, investor focus also shifts to non-oncology segments including Primary Care and Specialty Care. Key non-oncology products include Eliquis anticoagulant, Prevnar vaccines, COVID-19 vaccine Comirnaty, and newer drugs like RSV vaccine Abrysvo and migraine treatment Nurtec. Eliquis alliance revenues are expected to rise to $2.1 billion despite generic pressures. Prevnar vaccine sales likely declined in the U.S. but increased internationally, estimated at $1.64 billion. COVID-19 medication sales fell due to narrower vaccine recommendations and lower infections. In Specialty Care, Vyndaqel sales remain strong at an estimated $1.66 billion, while Xeljanz and Enbrel may have weakened. Pfizer's stock dropped 2.5% in past year, underperforming the industry, but trades at a forward price/earnings ratio of 8.58, suggesting valuation appeal.